<DOC>
	<DOCNO>NCT01932320</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption single dose two solid dose formulation relative nanosuspension formulation JNJ-40411813 ( Part 1 ) ; evaluate effect high-fat/high-calorie breakfast rate extent absorption select JNJ-40411813 solid dose formulation Part 1 ( Part 2 ) ; explore influence potent inhibitor CYP3A4 , ketoconazole , rate extent absorption select JNJ-40411813 solid dose formulation Part 1 ( Part 3 ) .</brief_summary>
	<brief_title>A Study Evaluate Relative Bioavailability , Food Effect Effect Ketoconazole Rate Extent Absorption Solid Dosage Formulation ( ) JNJ-40411813</brief_title>
	<detailed_description>This open-label ( physician participant know identity intervention ) single centre study . This study conduct 3 part ( Part 1 , Part 2 , Part 3 ) . The study consist 3 phase include , screen phase ( within 21 day prior start study medication ) , treatment phase ( Part 1 : 20 day ; Part 2 : 12 day ; Part 3 : 16 day ) , follow-up phase ( Part 1 Part 2 : approximately 14 day last administration study medication Part 3 : 14 day last administration ketaconazole ) . Approximately 36 participant enrol study ( 12 participant part ) . Part 1 randomize ( study medication assign chance ) 3-way cross-over ( method use switch participant one treatment arm another clinical study ) part study . Participants Part 1 randomly assign 1 3 treatment sequence ( Period 1 , Period 2 , Period 3 ) receive single dose 3 formulation JNJ-40411813 ( Formulation A : hard gelatin capsule fill bead ; Formulation B : immediate release tablet ; Formulation C : nanosuspension formulation ) without food . Each period separate wash period ( treatment ) least 1 week . Part 2 randomized 2-way cross-over part study . Participants Part 2 randomly assign 1 2 treatment sequence ( Period 1 Period 2 ) receive single dose select solid dose formulation JNJ-40411813 Part 1 without food food separate wash period least 1 week . Part 3 single-arm sequential ( carry stag approach ) part study . Participants Part 3 receive single dose select solid dose formulation JNJ-40411813 Part 1 two occasion ( Day 1 Day 10 ) without food along ketoconazole Day 6 Day 14 food . Safety evaluate assessment adverse event , vital sign , physical examination , 12-lead electrocardiogram , clinical laboratory test monitor throughout study . The total duration study participation participant 8 week .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Men must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug Body mass index ( BMI ) 18 30 kg/m2 ( BMI calculate weight [ kilogram ] divide square height [ meter ] ) Nonsmoker ( smoke 3 month prior screen ) Clinically significant abnormal value laboratory test abnormal physical examination History current significant unstable medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , lipid abnormality , bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , Parkinson 's disease , infection History epilepsy fit unexplained blackout significant history current psychiatric neurological illness Serology positive hepatitis B surface antigen , hepatitis C antibodies HIV antibody screen Positive urine screen drug abuse positive alcohol breath test screen start study medication Clinically significant acute illness within 7 day prior start study medication Use prescription medication overthecounter medication ( include paracetamol ) , herbal medication within 2 week start study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Relative Bioavailability</keyword>
	<keyword>Food effect</keyword>
	<keyword>JNJ-40411813</keyword>
	<keyword>Positive allosteric modulator</keyword>
	<keyword>Solid Dosage Formulation JNJ-40411813</keyword>
	<keyword>Ketoconazole</keyword>
</DOC>